Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526858 · ClinicalTrials.gov registry record · NA
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
A NA study of Resistant Hypertension, sponsored by DeepQure.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT06526858: Recruiting NA study of Resistant Hypertension, sponsored by DeepQure.
NCT06526858 is a NA study of Resistant Hypertension that is actively recruiting participants, run by DeepQure. The registered enrollment target is 15 participants, below the 3,412-participant average among 4 other Resistant Hypertension trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06526858, a NA study of Resistant Hypertension, is actively recruiting participants, sponsored by DeepQure.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications
Primary Outcome
Measure by 24-hour ambulatory blood pressure monitoring(ABPM)
Conditions Studied
Interventions
- DEVICE HyperQureTM Renal Denervation (RDN) System:
Study Locations (5)
California
- University of California Irvine - Orange
- Stanford Health Care - Stanford
Florida
- University of Florida College of Medicine - Gainesville
Michigan
- Henry Forth Health - Detroit
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2029-03-20 |
| Phase | NA |
What NCT06526858 shows while recruiting
NCT06526858 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 3,412-participant average among 4 other Resistant Hypertension trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Resistant Hypertension appearing as the primary indexed condition, and to 1 intervention - of which HyperQureTM Renal Denervation (RDN) System: is the first listed.
NCT06526858 lists 5 locations in 4 states (California, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT06526858 about?
NCT06526858 is a clinical study titled "Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension". HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications
What is the current status of trial NCT06526858?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-11-21. Estimated completion is 2029-03-20.
What conditions does trial NCT06526858 study?
This clinical trial studies the following conditions: Resistant Hypertension.
What interventions are being tested in trial NCT06526858?
The interventions under investigation include: HyperQureTM Renal Denervation (RDN) System: (DEVICE).
Who is sponsoring clinical trial NCT06526858?
This trial is sponsored by DeepQure, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526858 being conducted?
This trial has 5 study locations across California, Florida, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Resistant Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™
ACTIVE NOT RECRUITING · NA
-
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
ACTIVE NOT RECRUITING · NA
-
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI